Epidermal growth factor receptor mutations in lung adenocarcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Howlader NNA, Krapcho M, Garshell J et alSEER Cancer Statistics Review, 1975-2010. In: Institute. NC, ed. Bethesda, MD2013.
da Cunha Santos, 2011, EGFR mutations and lung cancer, Ann Rev Pathol, 6, 49, 10.1146/annurev-pathol-011110-130206
Hochhaus, 2004, Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), Ann Hematol, 83, S65
Khazaie, 1993, EGF receptor in neoplasia and metastasis, Cancer Metastasis Rev, 12, 255, 10.1007/BF00665957
Ullrich, 1990, Signal transduction by receptors with tyrosine kinase activity, Cell, 61, 203, 10.1016/0092-8674(90)90801-K
Carpenter, 1987, Receptors for epidermal growth factor and other polypeptide mitogens, Ann Rev Biochem, 56, 881, 10.1146/annurev.bi.56.070187.004313
Libermann, 1985, Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin, Nature, 313, 144, 10.1038/313144a0
Huang, 1997, The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling, J Biol Chem, 272, 2927, 10.1074/jbc.272.5.2927
Liebmann, 2001, Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity, Cell Signal, 13, 777, 10.1016/S0898-6568(01)00192-9
Jorissen, 2003, Epidermal growth factor receptor: mechanisms of activation and signalling, Exp Cell Res, 284, 31, 10.1016/S0014-4827(02)00098-8
Sos, 2009, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res, 69, 3256, 10.1158/0008-5472.CAN-08-4055
Guo, 2013, Molecular dissection of AKT activation in lung cancer cell lines, Mol Cancer Res, 11, 282, 10.1158/1541-7786.MCR-12-0558
Takata, 2012, STAT3 expression in activating EGFR-driven adenocarcinoma of the lung, Lung Cancer, 75, 24, 10.1016/j.lungcan.2011.05.015
Weinstein, 2006, Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy, Nat Clin Pract Oncol, 3, 448, 10.1038/ncponc0558
Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected], J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038
Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial, JAMA, 290, 2149, 10.1001/jama.290.16.2149
Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753
Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938
Pao, 2004, EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci USA, 101, 13306, 10.1073/pnas.0405220101
Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073
Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J. Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055
Tang, 2005, EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients, Cancer Res, 65, 7568, 10.1158/0008-5472.CAN-05-1705
Yoshida, 2005, Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung, Lung Cancer, 50, 1, 10.1016/j.lungcan.2005.04.012
Sakamoto, 2007, Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas, J Pathol, 212, 287, 10.1002/path.2165
Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857
Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314
Sakurada, 2006, Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations, Clin Lung Cancer, 7, S138, 10.3816/CLC.2006.s.005
Chou, 2005, Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer, Clin Cancer Res, 11, 3750, 10.1158/1078-0432.CCR-04-1981
Mitsudomi, 2005, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, J Clin Oncol, 23, 2513, 10.1200/JCO.2005.00.992
Yang, 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, J Clin Oncol, 26, 2745, 10.1200/JCO.2007.15.6695
Locatelli-Sanchez, 2013, Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes, Lung, 191, 491, 10.1007/s00408-013-9482-4
Lee, 2013, Association of Exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer, J Thorac Oncol, 8, 1148, 10.1097/JTO.0b013e31829f684a
Han, 2005, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol, 23, 2493, 10.1200/JCO.2005.01.388
Takano, 2005, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer, J Clin Oncol, 23, 6829, 10.1200/JCO.2005.01.0793
Wu, 2008, Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response, Clin Cancer Res, 14, 4877, 10.1158/1078-0432.CCR-07-5123
Asahina, 2006, Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L, Lung Cancer, 54, 419, 10.1016/j.lungcan.2006.09.005
Lund-Iversen, 2012, Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations, J Thorac Oncol, 7, 1471, 10.1097/JTO.0b013e3182614a9d
Greulich, 2005, Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants, PLoS Med, 2, e313, 10.1371/journal.pmed.0020313
Arcila, 2013, EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics, Mol Cancer Ther, 12, 220, 10.1158/1535-7163.MCT-12-0620
Rosell, 2011, Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations, Clin Cancer Res, 17, 1160, 10.1158/1078-0432.CCR-10-2158
Su, 2012, Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer, J Clin Oncol, 30, 433, 10.1200/JCO.2011.38.3224
Girard, 2010, Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report, Clin Cancer Res, 16, 755, 10.1158/1078-0432.CCR-09-2437
Gong, 2007, Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas, PLoS Med, 4, e294, 10.1371/journal.pmed.0040294
Siegelin, 2013, Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?, Cancer Lett, 333, 133, 10.1016/j.canlet.2013.01.045
Costa, 2007, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations, PLoS Med, 4, 1669, 10.1371/journal.pmed.0040315
Wei, 2013, EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance, Cell, 154, 1269, 10.1016/j.cell.2013.08.015
Han, 2011, EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells, PloS ONE, 6, e18691, 10.1371/journal.pone.0018691
Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238
Kosaka, 2006, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res, 12, 5764, 10.1158/1078-0432.CCR-06-0714
Balak, 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors, Clin Cancer Res, 12, 6494, 10.1158/1078-0432.CCR-06-1570
Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246
Oxnard, 2011, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation, Clin Cancer Res, 17, 1616, 10.1158/1078-0432.CCR-10-2692
Ramalingam, 2012, Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer, J Clin Oncol, 30, 3337, 10.1200/JCO.2011.40.9433
Miller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, Lancet Oncol, 13, 528, 10.1016/S1470-2045(12)70087-6
Yang, 2012, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial, Lancet Oncol, 13, 539, 10.1016/S1470-2045(12)70086-4
Zhou, 2009, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 462, 1070, 10.1038/nature08622
Turke, 2010, Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC, Cancer Cell, 17, 77, 10.1016/j.ccr.2009.11.022
Yano, 2008, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations, Cancer Res, 68, 9479, 10.1158/0008-5472.CAN-08-1643
Cheng, 2005, Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer, Chest, 128, 1453, 10.1016/S0012-3692(15)52173-9
Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478
Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product, Science, 251, 802, 10.1126/science.1846706
Graziani, 1991, The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase, J Biol Chem, 266, 22087, 10.1016/S0021-9258(18)54536-1
Watanabe, 2013, Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma, Lung Cancer, 82, 370, 10.1016/j.lungcan.2013.06.003
Popat, 2013, Transformation to ‘high grade’ neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma, Lung Cancer, 80, 1, 10.1016/j.lungcan.2012.12.019
Alam, 2010, Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung, Clinical Lung Cancer, 11, E1, 10.3816/CLC.2010.n.046
Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017
Takeda, 2010, De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer, J Thorac Oncol, 5, 399, 10.1097/JTO.0b013e3181cee47e
Sequist, 2011, Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer, J Clin Oncol, 29, 3307, 10.1200/JCO.2010.34.0570
Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br J Cancer, 91, 355, 10.1038/sj.bjc.6601894
Paik, 2011, Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations, J Clin Oncol, 29, 2046, 10.1200/JCO.2010.33.1280
Cardarella, 2013, Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer, Clin Cancer Res, 19, 4532, 10.1158/1078-0432.CCR-13-0657
Pao, 2011, New driver mutations in non-small-cell lung cancer, Lancet Oncol, 12, 175, 10.1016/S1470-2045(10)70087-5
Marks, 2008, Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma, Cancer Res, 68, 5524, 10.1158/0008-5472.CAN-08-0099
Cortot, 2013, Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway, Cancer Res, 73, 834, 10.1158/0008-5472.CAN-12-2066
Kang, 2005, Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic, Proc Natl Acad Sci USA, 102, 802, 10.1073/pnas.0408864102
Engelman, 2006, Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, J Clin Invest, 116, 2695, 10.1172/JCI28656
Buttitta, 2006, Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features, Int J Cancer, 119, 2586, 10.1002/ijc.22143
Ng, 2012, A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nat Med, 18, 521, 10.1038/nm.2713
Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945
Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin Cancer Res, 19, 4273, 10.1158/1078-0432.CCR-13-0318
Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448
Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993
Bergethon, 2012, ROS1 rearrangements define a unique molecular class of lung cancers, J Clin Oncol, 30, 863, 10.1200/JCO.2011.35.6345
Kim, 2013, The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma, Ann Oncol, 24, 2364, 10.1093/annonc/mdt220